tbuckley/cabot-search huggingface dataset:
Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study
Authors: Wei Kang, Jessica J. P. Shami, Vincent K. C. Yan, Xuxiao Ye, Joseph E. Blais, Xue Li, Victor H. F. Lee, Celine S. L. Chui, Francisco T. T. Lai, Eric Y. F. Wan, Carlos K. H. Wong, Ian C. K. Wong, Esther W. Chan
Journal: Journal of Hematology & Oncology (2022)

Abstract Background The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patients with cancer contributing to vaccine hesitancy in this population. We aimed to evaluate the association between BNT162b2 and CoronaVac vaccines and the risk of AESI in adults with active cancer or a history of cancer. Patients and methods We conducted a territory-wide cohort study using electronic health records managed by the Hong Kong Hospital Authority and vaccination records provided by the Department of Health. Patients with a cancer diagnosis between January 1, 2018, and September 30, 2021, were included and stratified into two cohorts: active cancer and history of cancer. Within each cohort, patients who received two doses of BNT162b2 or CoronaVac were 1:1 matched to unvaccinated patients using the propensity score. Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for AESI 28 days after the second vaccine dose. Results A total of 74,878 patients with cancer were included (vaccinated: 25,789 [34%]; unvaccinated: 49,089 [66%]). Among patients with active cancer, the incidence of AESI was 0.31 and 1.02 per 10,000 person-days with BNT162b2 versus unvaccinated patients and 0.13 and 0.88 per 10,000 person-days with CoronaVac versus unvaccinated patients. Among patients with history of cancer, the incidence was 0.55 and 0.89 per 10,000 person-days with BNT162b2 versus unvaccinated patients and 0.42 and 0.93 per 10,000 person-days with CoronaVac versus unvaccinated patients. Neither vaccine was associated with a higher risk of AESI for patients with active cancer (BNT162b2: HR 0.30, 95% CI 0.08–1.09; CoronaVac: 0.14, 95% CI 0.02–1.18) or patients with history of cancer (BNT162b2: 0.62, 95% CI 0.30–1.28; CoronaVac: 0.45, 95% CI 0.21–1.00). Conclusions In this territory-wide cohort study of patients with cancer, the incidence of AESI following vaccination with two doses of either BNT162b2 or CoronaVac vaccines was low. The findings of this study can reassure clinicians and patients with cancer about the overall safety of BNT162b2 and CoronaVac in patients with cancer, which could increase the COVID-19 vaccination rate in this vulnerable group of patients.
Worked to the bone: antibody-based conditioning as the future of transplant biology
Authors: James M. Griffin, Fiona M. Healy, Lekh N. Dahal, Yngvar Floisand, John F. Woolley
Journal: Journal of Hematology & Oncology (2022)

Abstract Conditioning of the bone marrow prior to haematopoietic stem cell transplant is essential in eradicating the primary cause of disease, facilitating donor cell engraftment and avoiding transplant rejection via immunosuppression. Standard conditioning regimens, typically comprising chemotherapy and/or radiotherapy, have proven successful in bone marrow clearance but are also associated with severe toxicities and high incidence of treatment-related mortality. Antibody-based conditioning is a developing field which, thus far, has largely shown an improved toxicity profile in experimental models and improved transplant outcomes, compared to traditional conditioning. Most antibody-based conditioning therapies involve monoclonal/naked antibodies, such as alemtuzumab for graft-versus-host disease prophylaxis and rituximab for Epstein–Barr virus prophylaxis, which are both in Phase II trials for inclusion in conditioning regimens. Nevertheless, alternative immune-based therapies, including antibody–drug conjugates, radio-labelled antibodies and CAR-T cells, are showing promise in a conditioning setting. Here, we analyse the current status of antibody-based drugs in pre-transplant conditioning regimens and assess their potential in the future of transplant biology.
Association between Outdoor Air Pollution Exposure and Handgrip Strength: Findings from the French CONSTANCES Study
Authors: Mohammad Javad Zare Sakhvidi, Antoine Lafontaine, Jun Yang, Emeline Lequy, Fanny Artaud, Marianne Canonico, Anna Ozguler, Danielle Vienneau, Marie Zins, Bénédicte Jacquemin
Journal: Environmental Health Perspectives (2022)
Agent Orange Exposure and Risk of Idiopathic Pulmonary Fibrosis among U.S. Veterans
Authors: Bhavika Kaul, Joyce S. Lee, David V. Glidden, Paul D. Blanc, Ning Zhang, Harold R. Collard, Mary A. Whooley
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: There is limited literature exploring the relationship between military exposures and idiopathic pulmonary fibrosis (IPF). Objectives: To evaluate whether exposure to Agent Orange is associated with an increased risk of IPF among veterans. Methods: We used Veterans Health Administration data to identify patients diagnosed with IPF between 2010 and 2019. We restricted the cohort to male Vietnam veterans and performed multivariate logistic regression to examine the association between presumptive Agent Orange exposure and IPF. We conducted sensitivity analyses restricting the cohort to army veterans (highest theoretical burden of exposure, surrogate for dose response) and a more specific case definition of IPF. Fine-Gray competing risk models were used to evaluate age to IPF diagnosis. Measurements and Main Results: Among 3.6 million male Vietnam veterans, 948,103 (26%) had presumptive Agent Orange exposure. IPF occurred in 2.2% of veterans with Agent Orange exposure versus 1.9% without exposure (odds ratio, 1.14; 95% confidence interval [CI], 1.12–1.16; P < 0.001). The relationship persisted after adjusting for known IPF risk factors (odds ratio, 1.08; 95% CI, 1.06–1.10; P < 0.001). The attributable risk among exposed veterans was 7% (95% CI, 5.3–8.7%; P < 0.001). Numerically greater risk was observed when restricting the cohort to 1) Vietnam veterans who served in the army and 2) a more specific definition of IPF. After accounting for the competing risk of death, veterans with Agent Orange exposure were still more likely to develop IPF. Conclusions: Presumptive Agent Orange exposure is associated with greater risk of IPF. Future research should validate this association and investigate the biological mechanisms involved.
Supporting Physicians Along the Entire Journey of Fertility and Family Building
Authors: Ariela L. Marshall, Arghavan Salles
Journal: JAMA Network Open (2022)

Kathryn S. Smith, BS; Jennifer B. Bakkensen, MD; Anne P. Hutchinson, MD; Elaine O. Cheung, PhD; Jessica Thomas, MA; Veronika Grote, BS; Patricia I. Moreno, PhD; Kara N. Goldman, MD; Neil Jordan, PhD; Eve C. Feinberg, MD
Perspectives on Use of the Cutaneous Direct Immunofluorescence Assay—Reply
Authors: Julie D. R. Reimann, Sean P. Moynihan, Thomas D. Horn
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance
Authors: Qing Xu, Gui Chen, Guimei Chen, Hualan Wu, Yuanyuan Yang, Ziyi Mai, Rui Sun, Ping Luan, Chaowan Guo, Meng Yu, Zhenwei Peng, Zhiqiang Yu
Journal: Journal of Controlled Release (2022)
Multi-functional vesicles improve Helicobacter pylori eradication by a comprehensive strategy based on complex pathological microenvironment
Authors: Xiaonan Chen, Yiqing Zou, Shuqi Zhang, Pengchao Fang, Shuxuan Li, Pengyu Li, Yingying Sun, Gang Yuan, Haiyan Hu
Journal: Acta Pharmaceutica Sinica B (2022)

Helicobacter pylori (H. pylori), creating a global infection rate over 50%, presents great challenges in clinical therapies due to its complex pathological microenvironment in vivo. To improve the eradication efficacy, herein we fabricated a pharmaceutical vesicle RHL/Cl-Ch-cal where cholesterol-PEG, calcitriol and first-line antibiotic clarithromycin were co-loaded in the rhamnolipid-composed outer lipid layer. RHL/Cl-Ch-cal could quickly penetrate through gastric mucus layer to reach H. pylori infection sites, and then effectively destroyed the architecture of H. pylori biofilms, killed dispersed H. pylori and inhibited the re-adhesion of residual bacteria (called biofilms eradication tetralogy). Moreover, RHL/Cl-Ch-cal activated the host immune response to H. pylori by replenishing cholesterol to repair lipid raft on the cell membrane of host epithelial cells. Finally, RHL/Cl-Ch-cal killed the intracellular H. pylori through recovering the lysosomal acidification and assisting degradation. In experiments, RHL/Cl-Ch-cal demonstrated prominent anti-H. pylori efficacy in the classical H. pylori-infected mice model. Therefore, the study provides a "comprehensive attack" strategy for anti-H. pylori therapies including biofilms eradication tetralogy, immune activation and intracellular bacteria killing.
Treatment of Aortic Stenosis With Transcatheter Aortic Valve Implantation
Authors: Catherine M. Otto, Jae-Kwan Song
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to Hyung Joon Kim and Khurshid R. Ghani’s Letter to the Editor re: Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland. Thulium Fibre Laser Versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. 2022;82:73–9
Authors: Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland
Journal: European Urology (2022)
Iron-based and BRD4-downregulated strategy for amplified ferroptosis based on pH-sensitive/NIR-II-boosted nano-matchbox
Authors: Lujing Geng, Tong Lu, Huaqing Jing, Yue Zhou, Xiaoyang Liang, Jiao Li, Nan Li
Journal: Acta Pharmaceutica Sinica B (2022)

Ferroptosis (FPT), a novel form of programmed cell death, is characterized by overwhelming iron/reactive oxygen species (ROS)-dependent accumulation of lipid peroxidation (LPO). However, the insufficiency of endogenous iron and ROS level limited the FPT therapeutic efficacy to a large extent. To overcome this obstacle, the bromodomain-containing protein 4 (BRD4)-inhibitor (+)-JQ1 (JQ1) and iron-supplement ferric ammonium citrate (FAC)-loaded gold nanorods (GNRs) are encapsulated into the zeolitic imidazolate framework-8 (ZIF-8) to form matchbox-like GNRs@JF/ZIF-8 for the amplified FPT therapy. The existence of matchbox (ZIF-8) is stable in physiologically neutral conditions but degradable in acidic environment, which could prevent the loaded agents from prematurely reacting. Moreover, GNRs as the drug-carriers induce the photothermal therapy (PTT) effect under the irradiation of near-infrared II (NIR-II) light owing to the absorption by localized surface plasmon resonance (LSPR), while the hyperthermia also boosts the JQ1 and FAC releasing in the tumor microenvironment (TME). On one hand, the FAC-induced Fenton/Fenton-like reactions in TME can simultaneously generate iron (Fe3+/Fe2+) and ROS to initiate the FPT treatment by LPO elevation. On the other hand, JQ1 as a small molecule inhibitor of BRD4 protein can amplify FPT through downregulating the expression of glutathione peroxidase 4 (GPX4), thus inhibiting the ROS elimination and leading to the LPO accumulation. Both in vitro and in vivo studies reveal that this pH-sensitive nano-matchbox achieves obvious suppression of tumor growth with good biosafety and biocompatibility. As a result, our study points out a PTT combined iron-based/BRD4-downregulated strategy for amplified ferrotherapy which also opens the door of future exploitation of ferrotherapy systems.
Metronomic dose-finding approach in oral chemotherapy by experimentally-driven integrative mathematical modeling
Authors: Seho Kweon, Yoo-Seong Jeong, Seung Woo Chung, Hanul Lee, Ha Kyeong Lee, Seong Jin Park, Jeong Uk Choi, Jooho Park, Suk-Jae Chung, Youngro Byun
Journal: Biomaterials (2022)
Making Value-Based Payment Work for Federally Qualified Health Centers
Authors: Amol S. Navathe, Pooja Chandrashekar, Christopher Chen
Journal: JAMA (2022)

This Viewpoint examines how engaging federally qualified health centers and other outpatient safety-net clinicians and health centers in value-based care can address health disparities faced by patients who have low income or are members of underrepresented racial and ethnic groups.
Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival
Authors: Marcus Alvarez, Jihane N. Benhammou, Nicholas Darci-Maher, Samuel W. French, Steven B. Han, Janet S. Sinsheimer, Vatche G. Agopian, Joseph R. Pisegna, Päivi Pajukanta
Journal: Genome Medicine (2022)

Abstract Background Hepatocellular carcinoma (HCC) is a common primary liver cancer with poor overall survival. We hypothesized that there are HCC-associated cell-types that impact patient survival. Methods We combined liver single nucleus (snRNA-seq), single cell (scRNA-seq), and bulk RNA-sequencing (RNA-seq) data to search for cell-type differences in HCC. To first identify cell-types in HCC, adjacent non-tumor tissue, and normal liver, we integrated single-cell level data from a healthy liver cohort ( n = 9 non-HCC samples) collected in the Strasbourg University Hospital; an HCC cohort ( n = 1 non-HCC, n = 14 HCC-tumor, and n = 14 adjacent non-tumor samples) collected in the Singapore General Hospital and National University; and another HCC cohort ( n = 3 HCC-tumor and n = 3 adjacent non-tumor samples) collected in the Dumont-UCLA Liver Cancer Center. We then leveraged these single cell level data to decompose the cell-types in liver bulk RNA-seq data from HCC patients’ tumor ( n = 361) and adjacent non-tumor tissue ( n = 49) from the Cancer Genome Atlas (TCGA) multi-center cohort. For replication, we decomposed 221 HCC and 209 adjacent non-tumor liver microarray samples from the Liver Cancer Institute (LCI) cohort collected by the Liver Cancer Institute and Zhongshan Hospital of Fudan University. Results We discovered a tumor-associated proliferative cell-type, Prol (80.4% tumor cells), enriched for cell cycle and mitosis genes. In the liver bulk tissue from the TCGA cohort, the proportion of the Prol cell-type is significantly increased in HCC and associates with a worse overall survival. Independently from our decomposition analysis, we reciprocally show that Prol nuclei/cells significantly over-express both tumor-elevated and survival-decreasing genes obtained from the bulk tissue. Our replication analysis in the LCI cohort confirmed that an increased estimated proportion of the Prol cell-type in HCC is a significant marker for a shorter overall survival. Finally, we show that somatic mutations in the tumor suppressor genes TP53 and RB1 are linked to an increase of the Prol cell-type in HCC. Conclusions By integrating liver single cell, single nucleus, and bulk expression data from multiple cohorts we identified a proliferating cell-type (Prol) enriched in HCC tumors, associated with a decreased overall survival, and linked to TP53 and RB1 somatic mutations.
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial
Authors: Emily E Coates, Srilatha Edupuganti, Grace L Chen, Myra Happe, Larisa Strom, Alicia Widge, Maria Burgos Florez, Josephine H Cox, Ingelise Gordon, Sarah Plummer, Abidemi Ola, Galina Yamshchikov, Charla Andrews, Sharon Curate-Ingram, Patricia Morgan, Shashi Nagar, Matthew H Collins, Amy Bray, Thuy Nguyen, Judy Stein, Christopher L Case, Florence Kaltovich, Diane Wycuff, C Jason Liang, Kevin Carlton, Sandra Vazquez, John R Mascola, Julie E Ledgerwood, Ellie Butler, Jean Winter, Jianguo Xu, Amy Sherman, Colleen Kelley, Rameses Fredrick, Nadine Rouphael, Varun Phadke, Cynthia Whitney, Alicarmen Alvarez, Renata Dennis, Rebecca Fineman, Pamela Lankford-Turner, Sha Yi, Lilin Lai, Gena Burch, Shanker Gupta, Nina Berkowitz, Cristina Carter, Allison Beck, Brenda Larkin, Stephanie Taylor, Mandy Alger, Jessica Bahorich, Amy Lynch Chamberlain, Ya-chen Chang, Rajoshi Chaudhuri, Jonathan Cooper, Jacob Demirji, Fan Yang, Alissa Fernald, Deepika Gollapudi, Janel Holland-Linn, Lisa Kueltzo, James Lee, Jie Liu, Xun Liu, Rachel Mowery, Sarah O'Connell, Erwin Rosales-Zavala, Jason Sands, Xin Wang, Shaojie Weng, Sara Witter
Journal: The Lancet Infectious Diseases (2022)
Rho-associated, coiled-coil–containing protein kinase 1 regulates development of diabetic kidney disease via modulation of fatty acid metabolism
Authors: Yosuke Nagai, Keiichiro Matoba, Yusuke Takeda, Hideji Yako, Tomoyo Akamine, Kensuke Sekiguchi, Yasushi Kanazawa, Tamotsu Yokota, Kazunori Sango, Daiji Kawanami, Kazunori Utsunomiya, Rimei Nishimura
Journal: Kidney International (2022)
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
Authors: Pablo Garcia-Valtanen, Christopher M. Hope, Makutiro G. Masavuli, Arthur Eng Lip Yeow, Harikrishnan Balachandran, Zelalem A. Mekonnen, Zahraa Al-Delfi, Arunasingam Abayasingam, David Agapiou, Alberto Ospina Stella, Anupriya Aggarwal, George Bouras, Jason Gummow, Catherine Ferguson, Stephanie O’Connor, Erin M. McCartney, David J. Lynn, Guy Maddern, Eric J. Gowans, Benjamin A.J. Reddi, David Shaw, Chuan Kok-Lim, Michael R. Beard, Daniela Weiskopf, Alessandro Sette, Stuart G. Turville, Rowena A. Bull, Simon C. Barry, Branka Grubor-Bauk
Journal: Cell Reports Medicine (2022)

Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of concern (VOCs) in mild-COVID-19 convalescents at 12 months after infection with ancestral virus. In this cohort, ancestral, receptor-binding domain (RBD)-specific antibody and circulating memory B cell levels are conserved in most individuals, and yet serum neutralization against live B.1.1.529 (Omicron) is completely abrogated and significantly reduced for other VOCs. Likewise, ancestral SARS-CoV-2-specific memory T cell frequencies are maintained in >50% of convalescents, but the cytokine response in these cells to mutated spike epitopes corresponding to B.1.1.529 and B.1.351 (Beta) VOCs were impaired. These results indicate that increased antigen variability in VOCs impairs humoral and spike-specific T cell immunity post-infection, strongly suggesting that COVID-19 convalescents are vulnerable and at risk of re-infection with VOCs, thus stressing the importance of vaccination programs.
Bacteroides ovatus-mediated CD27− MAIT cell activation is associated with obesity-related T2D progression
Authors: Yue Li, Yi Yang, Jin Wang, Peihong Cai, Mei Li, Xixiang Tang, Ying Tan, Yuchan Wang, Fan Zhang, Xiaofeng Wen, Qiaoxing Liang, Yuanpeng Nie, Tufeng Chen, Xiang Peng, Xuemin He, Yanhua Zhu, Guojun Shi, Wai W. Cheung, Lai Wei, Yanming Chen, Yan Lu
Journal: Cellular and Molecular Immunology (2022)
Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years
Authors: Janko van Beek, Pieter LA Fraaij, Carlo Giaquinto, Delane Shingadia, Peter Horby, Giuseppe Indolfi, Marion Koopmans
Journal: Eurosurveillance (2022)

An increase of acute hepatitis of unknown aetiology has been reported among children in multiple countries worldwide. With a rapid online survey among hospitals in and outside of Europe, we describe case numbers recorded from 1 January to 18 April 2022 vs the previous 5 years. Of 24 countries that responded, we identified 5/17 European and 1/7 non-European countries with an elevation in probable cases of unexplained acute hepatitis, and severe cases were elevated in five European countries.